PUBLIC COMPANY
save$SGPSpyGlass Pharma, Inc.
$SGP26.43-2.94%Aliso Viejo, CA, USupdated 2h ago
community read0 votes
pipeline
1
marketed
0
phase 3
1
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 3
Upcoming
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase1Evaluation of the Safety, Efficacy, Dose Response of the Bimatoprost Drug Ring System (BIM-DRS) in Pseudophakic Patients Diagnosed With Open Angle Glaucoma or Ocular Hypertension
- phase3Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)
- phase3Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)
- N/AEvaluation of the Safety and Effectiveness of the Bimatoprost Implant System / IOL Combination in Patients With Ocular Hypertension or Mild to Moderate Open-angle Glaucoma
- —Observational Study to Evaluate Long Term Outcomes for Ocular Hypertension and Glaucoma Patients Treated With the SpyGlass Bimatoprost Implant System / IOL Combination
- phase2Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution
🐶 Hiring Signal
next earnings Nov 5, 2026
News
no news has mentioned this company yet
Data sources
last refreshed 7m ago
Found something off?
comments(0)
5-min edit window · permanent after that